What is China Pharma Holding Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. China Pharma Holding's interest expense for the
three
months ended in Mar. 2024 was $ -0.04 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.30 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. China Pharma Holding's Operating Income for the
three
months ended in Mar. 2024 was $ -0.92 Mil. China Pharma Holding's Interest Expense for the
three
months ended in Mar. 2024 was $ -0.04 Mil.
China Pharma Holding did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
China Pharma Holding Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Pharma Holding (OTCPK:CPHI) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
China Pharma Holding's Interest Expense for the
three
months ended in Mar. 2024 was $-0.04 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-0.92 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $1.43 Mil.
China Pharma Holding's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| China Pharma Holding did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
China Pharma Holding (China Pharma Holding) Business Description
Traded in Other Exchanges
N/A
Address
Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Executives
| Ke Deng |
10 percent owner |
NO.17, JINPAN ROAD, SECOND FLOOR, HAIKOU F4 570216 |
| Frank Waung |
officer: Chief Financial Officer |
72 GREAT HILLS RD., SHORT HILLS NJ 07078 |
| G Michael Bennett |
director |
4/F, NO. 3 JINYUAN ROAD, DAXING DISTRICT INDUSTRIAL DEVELOPMENT A, BEIJING F4 102600 |
| Yingwen Zhang |
director |
NO. 5, UNIT 1, BLDG. 4, NO. 14 XIN NAN ZHI RD., CHENGDU, SICHUAN F4 610041 |
| Baowen Dong |
director |
NO.9, BLDG. 9, SOUTH PARK, NO. 24, SECTION 1, 1ST RING ROAD, CHENGDU, SICHUAN F4 610041 |
| Heung Mei Tsui |
director, 10 percent owner |
FLAT F, 3RD FL., MAYSON GARDEN BLDG., 68 HING FAT ST., CAUSEWAY BAY, HONG KONG F4 XXXXX |
| Zhilin Li |
officer: President and CEO |
2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVINCE F4 570216 |
| Jian Yang |
officer: Secretary |
NO. 1 HAOYUAN ROAD, XINHUA DISTRICT, HAIKOU, HAINAN PROVI F4 570216 |
| Xinhua Wu |
officer: CFO |
2/F JIAHAI BLDG., NO. 17 JINPAN ROAD, JINPAN INDUSTRY DEVELOPMENT, HAIKOU, HAINAN PROVI F4 570216 |
| George L Diamond |
10 percent owner |
174 FM 1830, ARGYLE TX 76226 |
| David F Brigante |
10 percent owner |
174FM 1830, ARGYLE TX 76226 |
| Marat Rosenberg |
10 percent owner |
17 FM 1830, ARGYLE TX 76226 |
| Halter Financial Investments Lp |
10 percent owner |
174 FM 1830, ARGYLE TX 76226 |
| Halter Financial Investments Gp Llc |
10 percent owner |
174 FM 1830, ARGYLE TX 76226 |
| Timothy P Halter |
director, 10 percent owner, officer: CEO, President & CFO |
174 FM 1830, ARGYLE TX 76226 |
China Pharma Holding (China Pharma Holding) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPHI has been successfully added to your 